Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
Tyler VE. Herbs of Choice. Binghamton, NY: Pharmaceutical Products Press, 1994.
Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.
McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, FL: CRC Press, LLC 1997.
McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
Jie KG, Bots ML, Vermeer C, et al. Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif Tissue Int 1996;59:352-6.
Lean ME, Noroozi M, Kelly I. Dietary flavonols protect diabetic human lymphocytes against oxidative damage to DNA. Diabetes 1999;48:176-81.
Freeland-Graves JH, Lin PH. Plasma uptake of manganese as affected by oral loads of manganese, calcium, milk, phosphorus, copper, and zinc. J Am Coll Nutr 1991;10:38-43.
Stewart JJ, Wood MJ, Wood CD, Mims ME. Effects of ginger on motion sickness susceptibility and gastric function. Pharmacology 1991;42:111-20.
Ritchie, J. A. and Truelove, S. C. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J 2-10-1979;1(6160):376-378.
Stieg, R. L. Double-blind study of belladonna-ergotamine-phenobarbital for interval treatment of recurrent throbbing headache. Headache 1977;17(3):120-124.
Friese KH, Kruse S, Ludtke R, and et al. The homoeopathic treatment of otitis media in children--comparisons with conventional therapy. Int J Clin Pharmacol Ther 1997;35(7):296-301.
Adigun, A. O. and Ajayi, A. A. Muscarinic blockade with oral hyoscine palliates angiotensin converting enzyme inhibitor induced cough. Afr.J Med Med Sci 1998;27(1-2):139.
Ripamonti, C., Mercadante, S., Groff, L., Zecca, E., De Conno, F., and Casuccio, A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom.Manage 2000;19(1):23-34.
Mercadante, S., Ripamonti, C., Casuccio, A., Zecca, E., and Groff, L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support.Care Cancer 2000;8(3):188-191.
Habib, A., Sharpe, P., Anderson, S., Francis, S., Davidson, A. C., and Smith, G. Buscopan for the treatment of pain after laparoscopic sterilisation. Anaesthesia 2001;56(2):174-176.
Poynard, T., Regimbeau, C., and Benhamou, Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment.Pharmacol Ther 2001;15(3):355-361.
Klocker, N., Hanschke, W., Toussaint, S., and Verse, T. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur.J Pharm Sci 2001;13(2):227-232.
Ciccaglione, A. F., Grossi, L., Cappello, G., Malatesta, M. G., Ferri, A., Toracchio, S., and Marzio, L. Effect of hyoscine N-butylbromide on gastroesophageal reflux in normal subjects and patients with gastroesophageal reflux disease. Am J Gastroenterol 2001;96(8):2306-2311.
PASSMORE, G. G. and SANTA CRUZ, E. W. The use of intravenous and intramuscular injections of demerol and scopolamine in labor and delivery. Am.J Obstet.Gynecol 1954;68(4):998-1008.
Spinks, A. B., Wasiak, J., Villanueva, E. V., and Bernath, V. Scopolamine for preventing and treating motion sickness. Cochrane.Database.Syst.Rev 2004;(3):CD002851.
Greenstein A, Chen J, and Matzkin H. Transdermal scopolamine in prevention of post open prostatectomy bladder contractions. Urology 1992;39(3):215-218.
Tsuji, M. H. and Yamashita, M. [Scopolamine butylbromide (0.2 mg.kg-1) prevents succinylcholine- induced bradycardia in infants and children]. Masui 1992;41(4):670-672.
Semple P, Madej T, Wheatley R, and et al. Transdermal hyoscine with patient-controlled analgesia. Anaesthesia 1992;47(5):399-401.
Nieto J, Abizanda J, Pico F, Valenzuela G, and et al. Transdermal scopolamine as treatment of bradyarrhythmias. Chest 1992;101(6):1588-1590.
Van der Burg, J. J., Jongerius, P. H., Van, Hulst K., Van, Limbeek J., and Rotteveel, J. J. Drooling in children with cerebral palsy: effect of salivary flow reduction on daily life and care. Dev.Med Child Neurol. 2006;48(2):103-107.
Kventsel, I., Berkovitch, M., Reiss, A., Bulkowstein, M., and Kozer, E. Scopolamine treatment for severe extra-pyramidal signs following organophosphate (chlorpyrifos) ingestion. Clin.Toxicol.(Phila) 2005;43(7):877-879.
Gillin J, Sutton, L., Ruiz C, and et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol.Psychiatry 7-15-1991;30(2):157-169.
Jones, S., Strobl, R., Crosby, D., Burkard, J. F., Maye, J., and Pellegrini, J. E. The effect of transdermal scopolamine on the incidence and severity of postoperative nausea and vomiting in a group of high-risk patients given prophylactic intravenous ondansetron. AANA.J 2006;74(2):127-132.
Soares, P. P., Porto, C. S., Abdalla, F. M., De La Fuente, R. N., Moreira, E. D., Krieger, E. M., and Irigoyen, M. C. Effects of rat sinoaortic denervation on the vagal responsiveness and expression of muscarinic acetylcholine receptors. J Cardiovasc.Pharmacol. 2006;47(3):331-336.
Nachum, Z., Shupak, A., and Gordon, C. R. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Clin.Pharmacokinet. 2006;45(6):543-566.
Furey, M. L. and Drevets, W. C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch.Gen.Psychiatry 2006;63(10):1121-1129.
White, P. F., Tang, J., Song, D., Coleman, J. E., Wender, R. H., Ogunnaike, B., Sloninsky, A., Kapu, R., Shah, M., and Webb, T. Transdermal scopolamine: an alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms. Anesth.Analg. 2007;104(1):92-96.
Siegel L and Klingbeil M. Control of drooling with transdermal scopolamine in a child with cerebral palsy. Dev.Med Child Neurol. 1991;33(11):1013-1014.
Toscano, A., Pancaro, C., and Peduto, V. A. Scopolamine prevents dreams during general anesthesia. Anesthesiology 2007;106(5):952-955.
Stromberg B, Reines D, and Ackerly J. Transderm scopolamine for the control of perioperative nausea. Am.Surg. 1991;57(11):712-715.
Estrada, A., Leduc, P. A., Curry, I. P., Phelps, S. E., and Fuller, D. R. Airsickness prevention in helicopter passengers. Aviat.Space Environ.Med 2007;78(4):408-413.
Spinks, A. B., Wasiak, J., Villanueva, E. V., and Bernath, V. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane.Database.Syst.Rev. 2007;(3):CD002851.
Harnett, M. J., O'Rourke, N., Walsh, M., Carabuena, J. M., and Segal, S. Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery. Anesth.Analg. 2007;105(3):764-769.
Samuels, L. A., Christie, L., Roberts-Gittens, B., Fletcher, H., and Frederick, J. The effect of hyoscine butylbromide on the first stage of labour in term pregnancies. BJOG. 2007;114(12):1542-1546.
Abernethy, A. P., Nixon, A., Fine, P. G., Peppin, J. F., Crossno, R. J., and Bull, J. Palliative care pharmacotherapy literature summaries and analyses. J Pain Palliat.Care Pharmacother. 2007;21(3):91-97.
Wee, B. and Hillier, R. Interventions for noisy breathing in patients near to death. Cochrane.Database.Syst.Rev. 2008;(1):CD005177.
Einarsson, J. I., Audbergsson, B. O., and Thorsteinsson, A. Scopolamine for prevention of postoperative nausea in gynecologic laparoscopy, a randomized trial. J Minim.Invasive.Gynecol. 2008;15(1):26-31.
Meijer, J. W., van Kuijk, A. A., Geurts, A. C., Schelhaas, H. J., and Zwarts, M. J. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am.J Phys.Med Rehabil. 2008;87(4):321-324.
Buchhalter, A. R., Fant, R. V., and Henningfield, J. E. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 2008;68(8):1067-1088.
Dreyfuss P, Vogel D, and Walsh N. The use of transdermal scopolamine to control drooling. A case report. Am J Phys.Med Rehabil. 1991;70(4):220-222.
Ferris, F. D., Kerr, I. G., Sone, M., and Marcuzzi, M. Transdermal scopolamine use in the control of narcotic-induced nausea. J Pain Symptom.Manage 1991;6(6):389-393.
Howland, J., Rohsenow, D. J., Minsky, S., Snoberg, J., Tagerud, S., Hunt, S. K., Almeida, A., Greece, J., and Allensworth-Davies, D. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time. Int J Occup.Environ.Health 2008;14(4):250-256.
Harris, S. N., Sevarino, F. B., Sinatra, R. S., Preble, L., O'Connor, T. Z., and Silverman, D. G. Nausea prophylaxis using transdermal scopolamine in the setting of patient-controlled analgesia. Obstet Gynecol 1991;78(4):673-677.
Antrobus, J. H., Abbott, P., Carr, C. M., and Chatrath, R. R. Midazolam-droperidol premedication for cardiac surgery. A comparison with papaveretum and hyoscine. Anaesthesia 1991;46(5):407-409.
Horimoto Y, Tomie H, Hanzawa K, and et al. Scopolamine patch reduces postoperative emesis in paediatric patients following strabismus surgery. Can.J Anaesth. 1991;38(4 Pt 1):441-444.
Wang, E. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action]. Zhonghua Er.Bi Yan.Hou Ke.Za Zhi 1990;25(5):299-302, 319.
Talmi Y, Finkelstein Y, and Zohar Y. Reduction of salivary flow with transdermal scopolamine: a four-year experience. Otolaryngol.Head Neck Surg. 1990;103(4):615-618.
Bailey, P. L., Streisand, J. B., Pace, N. L., Bubbers, S. J., East, K. A., Mulder, S., and Stanley, T. H. Transdermal scopolamine reduces nausea and vomiting after outpatient laparoscopy. Anesthesiology 1990;72(6):977-980.
Wood C, Stewart J, Wood M, and et al. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness. Aviat.Space Environ.Med 1990;61(2):157-161.
Cornella J, Bent A, Ostergard D, and et al. Prospective study utilizing transdermal scopolamine in detrusor instability. Urology 1990;35(1):96-97.
Koski E, Mattila M, Knapik D, and et al. Double blind comparison of transdermal hyoscine and placebo for the prevention of postoperative nausea. Br.J.Anaesth. 1990;64(1):16-20.
Talmi Y, Finkelstein Y, and Zohar Y. Reduction of salivary flow in amyotrophic lateral sclerosis with Scopoderm TTS. Head Neck 1989;11(6):565.
Shupak A, Gordon C, Spitzer O, and et al. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects. Pharmatherapeutica 1989;5(6):365-370.
Jespersen, T. W., Koch, J., Anker-Moller, E., Spangsberg, N. L., Johansen, U. T., and Grydehoj, P. [Transdermal scopolamine to prevent postoperative nausea and vomiting after uterine curettage and termination of pregnancy. A double-blind clinically controlled study with placebo]. Ugeskr Laeger 5-15-1989;151(20):1246-1248.
Wilkinson A, Frampton C, Glover P, and et al. Preoperative transdermal hyoscine for the prevention of postoperative nausea and vomiting. Anaesth.Intensive Care 1989;17(3):285-289.
Kotelko D, Rottman R, Wright W, and et al. Transdermal scopolamine decreases nausea and vomiting following cesarean section in patients receiving epidural morphine. Anesthesiology 1989;71(5):675-678.
Loper, K. A., Ready, L. B., and Dorman, B. H. Prophylactic transdermal scopolamine patches reduce nausea in postoperative patients receiving epidural morphine. Anesth.Analg. 1989;68(2):144-146.
Brodtkorb E, Wyzocka-Bakowska M, Lillevold P, and . Transdermal scopolamine in drooling. J Ment.Defic.Res 1988;32 ( Pt 3):233-237.
Tigerstedt I, Salmela L, and Aromaa U. Double-blind comparison of transdermal scopolamine, droperidol and placebo against postoperative nausea and vomiting. Acta Anaesthesiol.Scand. 1988;32(6):454-457.
Meyer, B. R., O'Mara, V., and Reidenberg, M. M. A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen. J Clin Oncol 1987;5(12):1994-1997.
Talmi Y, Finkelstein Y, Zohar Y, and et al. Reduction of salivary flow with Scopoderm TTS. Ann.Otol.Rhinol.Laryngol. 1988;97(2 Pt 1):128-130.
Mukerji V, Alpert M, Sanfelippo J, and et al. Treatment of chronic symptomatic supraventricular bradyarrhythmias with transdermal scopolamine. Chest 1988;94(1):204-205.
Markkanen, Y. J. and Pihlajamaki, K. Oral scopolamine hydrobromide solution as an antisialagogic agent in dentistry. Oral Surg Oral Med Oral Pathol 1987;63(4):417-420.
Offenloch, K., Zahner, G., Dietlein, G., and Franz, I. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions]. Arzneimittelforschung. 1986;36(9):1401-1406.
Tolksdorf, W., Baumann, S., Heine, C., and Hettenbach, A. [Effects and side effects of transdermal scopolamine for premedication in general anesthesia in elderly patients]. Anasth.Intensivther.Notfallmed. 1986;21(6):301-306.
Schneider, M. and Palas, T. A. [Morphine and scopolamine in premedication. A comparison of peroral and transdermal administration with intramuscular injections]. Anaesthesist 1986;35(3):193-196.
Wiener L, Baum N, and Suarez G. New method for management of detrusor instability: transdermal scopolamine. Urology 1986;28(3):208-210.
Demeter, S. L. and Cordasco, E. M. Transdermal scopolamine in the treatment of asthma: a preliminary report. J Asthma 1986;23(4):203-206.
Richardson, C. T. and Feldman, M. Effects of transdermal scopolamine, alone or in combination with cimetidine, on total 24 hour gastric acid secretion in patients with duodenal ulcer. Gut 1986;27(12):1493-1497.
Raeder, J. C., van der, Linden J., and Breivik, H. Premedication for day-case surgery: double-blind comparison of ketobemidone + dimethylaminodiphenylbuten (A-29) and morphine + scopolamine. Acta Anaesthesiol.Scand 1986;30(7):502-506.
Attias J, Gordon C, Ribak J, and et al. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea. Aviat.Space Environ.Med 1987;58(1):60-62.
Rahko, T. and Karma, P. Transdermal scopolamine for peripheral vertigo (a double-blind study). J Laryngol Otol 1985;99(7):653-656.
Pyykko, I., Padoan, S., Schalen, L., Lyttkens, L., Magnusson, M., and Henriksson, N. G. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Aviat.Space Environ Med 1985;56(8):777-782.
McCauley M, Royal J, Shaw J, and et al. Effect of transdermally administered scopolamine in preventing motion sickness. Aviat.Space Environ.Med. 1979;50(11):1108-1111.
Schmitt, L. G. and Shaw, J. E. Alleviation of induced vertigo. Therapy with transdermal scopolamine and oral meclizine. Arch Otolaryngol.Head Neck Surg 1986;112(1):88-91.
Aronson, J. K. and Sear, J. W. Transdermal hyoscine (scopolamine) and postoperative vomiting. Anaesthesia 1986;41(1):1-3.
Uppington J, Dunnet J, and Blogg C. Transdermal hyoscine and postoperative nausea and vomiting. Anaesthesia 1986;41(1):16-20.
Pyykko, I., Schalen, L., and Matsuoka, I. Transdermally administered scopolamine vs. dimenhydrinate. II. Effect on different types of nystagmus. Acta Otolaryngol. 1985;99(5-6):597-604.
van Marion, W. F., Bongaerts, M. C., Christiaanse, J. C., Hofkamp, H. G., and van Ouwerkerk, W. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas. Clin Pharmacol Ther 1985;38(3):301-305.
Palm L and Blennow G. Transdermal anticholinergic treatment of reflex anoxic seizures. Acta Paediatr.Scand. 1985;74(5):803-804.
Tolksdorf, W., Meisel, R., Muller, P., and Bender, H. J. [Transdermal scopolamine (TTS-scopolamine) for the prevention of postoperative nausea and vomiting]. Anaesthesist 1985;34(12):656-662.
Brand, J. J. and Whittingham, P. Intramuscular hyoscine in control of motion sickness. Lancet 8-1-1970;2(7666):232-234.
Sieg, H. [Double blind test using hyoscine-N-butyl bromide (Buscopan) to reduce pain in ulcus ventriculi]. Z Gastroenterol 1974;12(4):235-238.
Goulston K. Diagnosis and treatment of the irritable bowel syndrome. Drugs 1973;6(3):237-243.
Brand, J. J., Colquhoun, W. P., Gould, A. H., and Perry, W. L. (--)-Hyoscine and cyclizine as motion sickness remedies. Br.J Pharmacol. 1967;30(3):463-469.
Walan, A. Studies on peptic ulcer disease with special reference to the effect of l-hyoscyamine. Acta Med Scand Suppl 1970;516:5-57.
Conner, J. T., Bellville, J. W., Wender, R., Schehl, D., Dorey, F., and Katz, R. L. Morphine, scopolamine, and atropine as intravenous surgical premedicants. Anesth.Analg. 1977;56(5):606-614.
Clarke, R. S., Dundee, J. W., and Love, W. J. Studies of drugs given before anaesthesia. 8. Morphine 10 mg alone and with atropine or hyoscine. Br J Anaesth 1965;37(10):772-778.
Tokola, O., Laitinen, L. A., Aho, J., Gothoni, G., and Vapaatalo, H. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations. Aviat.Space Environ Med 1984;55(7):636-641.
Gleiter, C. H., Antonin, K. H., Brodrick, T., Bieck, P. R., and Breucha, G. Transdermal scopolamine and basal acid secretion. N Engl J Med 11-22-1984;311(21):1378.
Becker, G., Goossens, H., Seemann, K., Souchon, F., and Weitz, T. [Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy]. Dtsch Med Wochenschr 12-7-1984;109(49):1881-1885.
Noy S, Shapira S, Zilbiger A, and et al. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea. Aviat.Space Environ.Med 1984;55(11):1051-1054.
Homick, J. L., Kohl, R. L., Reschke, M. F., Degioanni, J., and Cintron-Trevino, N. M. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy. Aviat.Space Environ Med 1983;54(11):994-1000.
Rogawski M. Transdermal scopolamine and sialorrhea. Arch.Neurol. 1984;41(1):15.
Babin R, Balkany T, and Fee W. Transdermal scopolamine in the treatment of acute vertigo. Ann.Otol.Rhinol.Laryngol. 1984;93(1 Pt 1):25-27.
Dahl E, Offer-Ohlsen D, Lillevold P, and et al. Transdermal scopolamine, oral meclizine, and placebo in motion sickness. Clin Pharmacol Ther 1984;36(1):116-120.
Walt R, Kalman C, Hunt R, and et al. Effect of transdermally administered hyoscine methobromide on nocturnal acid secretion in patients with duodenal ulcer. Br.Med.J.(Clin Res.Ed) 6-12-1982;284(6331):1736-1738.
Longo, D. L., Wesley, M., Howser, D., Hubbard, S. M., Anderson, T., and Young, R. C. Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis. Cancer Treat.Rep 1982;66(11):1975-1976.
Cronin, C. M., Sallan, S. E., and Wolfe, L. Transdermal scopolamine in motion sickness. Pharmacotherapy 1982;2(1):29-31.
Price N, Schmitt L, McGuire J, and et al. Transdermal scopolamine in the prevention of motion sickness at sea. Clin.Pharmacol.Ther. 1981;29(3):414-419.
Laitinen, L. A., Tokola, O., Gothoni, G., and Vapaatalo, H. Scopolamine alone or combined with ephedrine in seasickness: a double- blind, placebo-controlled study. Aviat Space Environ Med 1981;52(1):6-10.
Anonymous. Transdermal scopolamine for motion sickness. Medical Letter on Drugs and Therapeutics 10-16-1981;23(21):89-90.
Graybiel A, Cramer D, and Wood C. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Aviat.Space Environ.Med. 1982;53(8):770-772.
Graybiel, A., Cramer, D. B., and Wood, C. D. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine. Aviat.Space Environ.Med 1981;52(6):337-339.
Lewis D, Fontana C, Mehallick L, and et al. Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev.Med Child Neurol. 1994;36(6):484-486.
Thune, A., Appelgren, L., and Haglind, E. Prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. A prospective randomized study of metoclopramide and transdermal hyoscine. Eur J Surg 1995;161(4):265-268.
Reinhart D, Klein K, and Schroff E. Transdermal scopolamine for the reduction of postoperative nausea in outpatient ear surgery: a double-blind, randomized study. Anesth.Analg. 1994;79(2):281-284.
Bradford, T. H., Robertson, K., Norman, P. F., and Meeks, G. R. Reduction of pain and nausea after laparoscopic sterilization with bupivacaine, metoclopramide, scopolamine, ketorolac, and gastric suctioning. Obstet Gynecol 1995;85(5 Pt 1):687-691.
Guldbrand P and Mellstrom A. Rectal versus intramuscular morphine-scopolamine as premedication in children. Acta Anaesthesiol.Scand 1995;39(2):224-227.
Honkavaara P, Saarnivaara L, and Klemola U. Prevention of nausea and vomiting with transdermal hyoscine in adults after middle ear surgery during general anaesthesia. Br.J Anaesth. 1994;73(6):763-766.
Graybiel, A., Knepton, J., and Shaw, J. Prevention of experimental motion sickness by scopolamine absorbed through the skin. Aviat.Space Environ Med 1976;47(10):1096-1100.
Pingree, B. J. and Pethybridge, R. J. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness. Aviat.Space Environ Med 1994;65(7):597-605.
La Rovere M, Mortara A, Pantaleo P, and et al. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 1994;90(2):838-843.
Doyle, E., Byers, G., McNicol, L. R., and Morton, N. S. Prevention of postoperative nausea and vomiting with transdermal hyoscine in children using patient-controlled analgesia. Br J Anaesth. 1994;72(1):72-76.
Vybiral T, Glaeser D, Morris G, and et al. Effects of low dose transdermal scopolamine on heart rate variability in acute myocardial infarction. J Am.Coll.Cardiol. 11-1-1993;22(5):1320-1326.
De Ferrari G, Mantica M, Vanoli E, et al, and . Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction. J Am.Coll.Cardiol. 11-1-1993;22(5):1327-1334.
Kohl R, Sandoz G, Reschke M, and et al. Facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine. J Clin Pharmacol 1993;33(11):1092-1103.
Casadei B, Pipilis A, Sessa F, and et al. Low doses of scopolamine increase cardiac vagal tone in the acute phase of myocardial infarction. Circulation 1993;88(2):353-357.
Pedretti R, Colombo E, and Braga S. Influence of transdermal scopolamine on cardiac sympathovagal interaction after acute myocardial infarction. Am.J Cardiol. 8-15-1993;72(5):384-392.
Moscovici R, Prego G, Schwartz M, and et al. Epidural scopolamine administration in preventing nausea after epidural morphine. J Clin Anesth. 1995;7(6):474-476.
Honkavaara P. Effect of transdermal hyoscine on nausea and vomiting during and after middle ear surgery under local anaesthesia. Br J Anaesth. 1996;76(1):49-53.
Lee T, Su S, Chen M, and et al. Usefulness of transdermal scopolamine for vasovagal syncope. Am.J Cardiol. 8-15-1996;78(4):480-482.
Yang, G., Xu, K., and Luo, Q. [Clinical study of scopolamine detoxification for the treatment of heroin addicts]. Zhonghua Yi Xue.Za Zhi 1996;76(2):141-144.
Venkatesh G, Fallen E, Kamath M, and et al. Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure. Heart 1996;76(2):137-143.
Casadei B, Conway J, Forfar C, and et al. Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure. Heart 1996;75(3):274-280.
Tarkkila P, Torn K, Tuominen M, and et al. Premedication with promethazine and transdermal scopolamine reduces the incidence of nausea and vomiting after intrathecal morphine. Acta Anaesthesiol.Scand 1995;39(7):983-986.
Bennett, M. I. Death rattle: an audit of hyoscine (scopolamine) use and review of management. J Pain Symptom.Manage. 1996;12(4):229-233.
Muskat Y, Bukovsky I, Schneider D, and et al. The use of scopolamine in the treatment of detrusor instability. J Urol. 1996;156(6):1989-1990.
Eberhart, L. H., Holzrichter, P., and Roscher, R. [Transdermal scopolamine for prevention of postoperative nausea and vomiting. No clinically relevant result in spite of reduced postoperative vomiting in general surgical and gynecologic patients]. Anaesthesist 1996;45(3):259-267.
Kramer U and Harel S. Transdermal scopolamine for refractory seizures. J Child Neurol. 1997;12(2):139-141.
Golding, J. F. and Stott, J. R. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br.J Clin.Pharmacol. 1997;43(6):633-637.
Ohkawa, T., Morimoto, S., Okuyama, A., Yoshioka, T., Kishimoto, T., Kurita, T., Ikoma, F., Itatani, H., Koide, T., and Ogawa, N. [Clinical phase III study of cimetropium bromide (DA3177) on the pain with upper urinary calculus: a double-blind study in comparison with scopolamine butylbromide. DA3177 Study Group]. Hinyokika Kiyo 1997;43(7):525-538.
Vesalainen, R. K., Kaila, T. J., Kantola, I. M., Tahvanainen, K. U., Juhani Airaksinen, K. E., Kuusela, T. A., and Eckberg, D. L. Low-dose transdermal scopolamine decreases blood pressure in mild essential hypertension. J Hypertens. 1998;16(3):321-329.
Al-Waili, N. and Saloom, K. Y. The analgesic effect of intravenous tenoxicam in symptomatic treatment of biliary colic: a comparison with hyoscine N-butylbromide. Eur J Med Res 10-14-1998;3(10):475-479.
Honkavaara P and Pyykko I. Effects of atropine and scopolamine on bradycardia and emetic symptoms in otoplasty. Laryngoscope 1999;109(1):108-112.
No authors. Putting a patch on postop nausea. Nursing 2007;37(1):0.
Gibbons PA, Nicolson SC, Betts EK, and et al. Scopolamine does not prevent post-operative emesis after pediatric eye surgery. Anesthesiology 1984;61(3A):A435.
Douma WR, Bosman IJ, Rutgers SR, and et al. Effects of transdermal scopolamine on pulmonary function, symptoms and bronchial hyperresponsiveness to methacholine. Eur J Pharm Sci 1998;5(6):327-334.
Bosman IJ. Chapter 8. Effects of transdermal scopolamine on pulmonary function and symptoms in patients with (partially) reversible airways obstruction. Transdermal Delivery of Anticholinergic Bronchodilators. Methodological and Clinical Aspects. Groningen: Rijksuniversiteit Groningen;1996.
De Ferrari GM, Mantica M, Curcuruto P, and et al. Transdermal scopolamine modifies autonomic balance after myocardial infarction [abstract]. Circulation 1991;84(4):II-266.
Casadei B, Pipilis A, Sessa F, and et al. Transdermal scopolamine: a potential tool in preventing sudden death in myocardial infarction [abstract]. Eur Heart J 1991;12 (Suppl):366.
Casadei B, Pipilis A, Conway J, and et al. Effects of vagal stimulation by transdermal scopolamine in patients post myocardial infarction [abstract]. Circulation 1991;84 (Suppl 2):II-555.
Chung-Hua H. [Successful use of scopolamine in acute myocardial infarction associated with resistant ventricular tachycardia]. Chin J Cardiol 1986;14(5):282-283.
Villanueva E, Clar C, Wasiak J, and et al. Scopolamine for preventing and treating motion sickness [protocol]. Cochrane Database Systematic Reviews 2001;(4)
Price N, Schmitt LG, and Shaw JE. Transdermal delivery of scopolamine for prevention of motion-induced nausea in rough seas. Clin Ther 1979;2:258-262.
Degioanni JJ, Calkins DS, and Reschke MF. Evaluation of the efficacy of buccal scopolamine tablets (1.0 mg) in the treatment of acute motion sickness [abstract]. Aviat Space Environ Med 1990;61:484.
Jackson SH, Schmitt L, McGuire J, and et al. Transdermal scopolamine as a preanesthetic drug and postoperative antinauseant and antimetic [abstract]. Anesthesiology 1982;57(3):A330.
Bosek V and Downs JB. Nausea and vomiting after Alfentanil anesthesia: effect of transdermal scopolamine. Anesthesiol Rev 1992;19(1):19-22.
Bosman IJ. Chapter 9. Effects of transdermal scopolamine on bronchial hyperresponsiveness to methacholine. Transdermal Delivery of Anticholinergic Bronchodilators. Methodological and Clinical Aspects. Groningen: Rijksuniversiteit Groningen;1996.
Dukoff R, Friz J, Lasser, and et al. A comparison of effects of tacrine with scopolamine versus tacrine with placebo in patients with Alzheimer's disease [abstract]. 11th Annual Meeting of the American Association for Geriatric Psychiatry 1998;
Kompanje, E. J. O. 'Death rattle' after withdrawal of mechanical ventilation: practical and ethical considerations. Intensive & Critical Care Nursing 2006;22(4):214-219.
Meyer BR, Lewin M, Pasmantier M, and et al. Clinical trial of diazepam or scopolamine with metoclopramide to ameliorate cis-platinum induced emesis [abstract]. Clin Pharmacol Ther 1983;33 :222.
Recto CP, Co TV, and Clemente V. The effect of hyoscine-n-butylbromide on the first stage of labor: a clinical trial [abstract]. Acta Obstetricia et Gynecologica Scandinavica Supplement 1997;76(167):45.
Vybiral T, Bryg R, Maddens M, and et al. Parasympathetic stimulation with transdermal scopolamine increases heart rate variability in acute myocardial infarction - a preliminary report [abstract]. Clin Res 1990;38(2):337A.
Messer SN. Homeopathic treatment of pediatric otitis media. J Am-Inst Homepathy 1987;80:15-21.
Clarke RS, Dundee JW, and Moore J. Studies of drugs given before anaesthesia. VI. Atropine and hyoscine. Br J Anaesth 1964;36:648-654.
Mora Durban MJ, Extramiana Cameno J, Arrizabalaga Moreno M, and et al. [Flubiprofen vs dipyrone combined with hyoscine: the analgesic efficacy in renal colic] (spanish). Arch Esp Urol 1995;48(9):867-873.
Lloret J, Muñoz J, Monmany J, and et al. Treatment of renal colic with dipyrone. A double-blind comparison trial with hyoscine alone or combined with dipyrone. Curr Ther Res 1987;42(6):1119-1128.
Longo D, Howser D, Wesley M, and et al. Randomized double-blind crossover trial of scopolamine vs. placebo administered by transcutaneous patch for the control of chemotherapy-induced emesis [abstract]. Proc Am Assoc Cancer Res 1981;22:161.
Pedersen JE. Scopolamine as sole pre-anaesthetic medication. Acta Anaesth Scandinav 1963;7:121-129.
Galeone M, Cacioli, D, Megevand J, and et al. Selection of the first-line treatment of irritable bowel syndrome - a prospective, randomised evaluation of fenoverine and hyoscine butyl bromide. European Journal of Clinical Research 1992;3:157-170.
Khadra I, Scott GC, and Braun SR. Transdermal scopolamine attenuates airways reactivity in asymptomatic asthmatics [abstract]. Am Rev Resp Dis 1988;137:329.
Miyoshi A. A multi-centre, double-blind evaluation against placebo of the therapeutic effect of hyosine-N-butylbromide in patients with abdominal pain. Pharmatherapeutica 1976;1(1):46-51.
Casadei B, Conway J, Meyer TE, and et al. Effect of vagal stimulation by transdermal scopolamine on exercise performance and R-R interval variability (RRV) in patients with chronic heart failure (CHF) [abstract]. Circulation 1992;86 (Suppl 1):I-395.
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2025 by Therapeutic Research Center, LLC. All Rights Reserved.